1. Home
  2. BROS vs JAZZ Comparison

BROS vs JAZZ Comparison

Compare BROS & JAZZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BROS
  • JAZZ
  • Stock Information
  • Founded
  • BROS 1992
  • JAZZ 2003
  • Country
  • BROS United States
  • JAZZ Ireland
  • Employees
  • BROS N/A
  • JAZZ N/A
  • Industry
  • BROS Restaurants
  • JAZZ Biotechnology: Pharmaceutical Preparations
  • Sector
  • BROS Consumer Discretionary
  • JAZZ Health Care
  • Exchange
  • BROS Nasdaq
  • JAZZ Nasdaq
  • Market Cap
  • BROS 7.4B
  • JAZZ 7.9B
  • IPO Year
  • BROS 2021
  • JAZZ 2007
  • Fundamental
  • Price
  • BROS $48.05
  • JAZZ $137.24
  • Analyst Decision
  • BROS Strong Buy
  • JAZZ Strong Buy
  • Analyst Count
  • BROS 18
  • JAZZ 14
  • Target Price
  • BROS $80.83
  • JAZZ $179.21
  • AVG Volume (30 Days)
  • BROS 3.9M
  • JAZZ 758.5K
  • Earning Date
  • BROS 11-05-2025
  • JAZZ 11-05-2025
  • Dividend Yield
  • BROS N/A
  • JAZZ N/A
  • EPS Growth
  • BROS 75.89
  • JAZZ N/A
  • EPS
  • BROS 0.48
  • JAZZ N/A
  • Revenue
  • BROS $1,451,963,000.00
  • JAZZ $4,086,695,000.00
  • Revenue This Year
  • BROS $27.79
  • JAZZ $5.70
  • Revenue Next Year
  • BROS $24.86
  • JAZZ $6.16
  • P/E Ratio
  • BROS $99.45
  • JAZZ N/A
  • Revenue Growth
  • BROS 29.80
  • JAZZ 4.52
  • 52 Week Low
  • BROS $30.49
  • JAZZ $95.49
  • 52 Week High
  • BROS $86.88
  • JAZZ $148.06
  • Technical
  • Relative Strength Index (RSI)
  • BROS 23.72
  • JAZZ 64.86
  • Support Level
  • BROS $51.12
  • JAZZ $134.26
  • Resistance Level
  • BROS $52.68
  • JAZZ $140.39
  • Average True Range (ATR)
  • BROS 1.74
  • JAZZ 3.05
  • MACD
  • BROS -0.65
  • JAZZ 0.35
  • Stochastic Oscillator
  • BROS 0.75
  • JAZZ 75.62

About BROS Dutch Bros Inc.

Dutch Bros Inc is an operator and franchisor of drive-thru coffee shops that are focused on serving hand-crafted beverages. The company's hand-crafted beverage-focused lineup features hot and cold espresso-based beverages, cold brew coffee products, proprietary energy drinks, tea, lemonade, smoothies and other beverages. The company has two reportable operating segments Company-operated shops and Franchising. It derives maximum revenue from Company operated shops.

About JAZZ Jazz Pharmaceuticals plc (Ireland)

Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.

Share on Social Networks: